Table 3 Radiation dose rate, elapsed time, and cumulative dose due to staff exposure to thyroid cancer patients treated with RAI-131 for the Group-B
Phase | Range, average dose rate (μSv/h) | Elapsed time, (min) | Average accumulative dose, (μSv) | Dose reduction factor (FR) | Γ,( μSv m2/MBq h) |
|---|---|---|---|---|---|
2 h | (73.7–101.9) | 1.3 ± 0.2 | 1.9 ± 0.6 | 0.999 | 0.019 ± 0.004 |
87.8 ± 14.0 | |||||
Second day | (16.5–34.7) | 1.5 ± 0.3 | 0.6 ± 0.4 | 0.998 | 0.006 ± 0.002 |
25.6 ± 9.0 | |||||
Third day | (11.3–4.9) | 2.0 ± 0.1 | 0.3 ± 0.1 | 0.997 | 0.002 ± 0.001 |
8.1 ± 5.0 | |||||
Fourth day | (1.5–5.3) | 2.2 ± 0.5 | 0.1 ± 0.1 | 0.995 | 0.001 ± 0.001 |
3.4 ± 2.0 | |||||
Fifth day | (3.6–1.2) | 2.5 ± 0.9 | 0.1 ± 0.1 | 0.993 | 0.001 ± 0.001 |
2.4 ± 1.0 |